Clinical Trial Detail

NCT ID NCT02264678
Title Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors AstraZeneca
Indications

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

gastric adenocarcinoma

lung adenocarcinoma

non-small cell lung carcinoma

Advanced Solid Tumor

Therapies

AZD6738

AZD6738 + Carboplatin

AZD6738 + Durvalumab

AZD6738 + Olaparib

Age Groups: senior adult

Additional content available in CKB BOOST